8-K: ESSA Pharma Acquired by XenoTherapeutics for $0.1242/Share

ESSA Pharma Inc. announced the completion of its acquisition by XenoTherapeutics, with shareholders receiving cash and contingent value rights.

Summary

• ESSA Pharma Inc. has been acquired by XenoTherapeutics, Inc. through its wholly-owned subsidiary, Xeno Acquisition Corp.
• The acquisition, structured as a plan of arrangement, was consummated on October 9, 2025.
• Each outstanding common share of ESSA was converted into the right to receive US$0.1242 in cash.
• Shareholders also received one contingent value right (CVR) per share, which represents the right to receive up to approximately US$0.14 per CVR.
• The potential CVR payment of US$0.14 per share represents up to US$6.7 million in aggregate, contingent on the outcome and related expenses of certain contingent liabilities.
• ESSA has requested the Nasdaq Capital Market to suspend trading of its common shares effective before the opening of trading on October 10, 2025.
• The company will also initiate the process to delist its shares from Nasdaq and terminate its registration under the U.S. Securities Exchange Act of 1934, ceasing its public reporting obligations.
• As a result of the arrangement, ESSA Pharma Inc. is now a wholly-owned subsidiary of Xeno Acquisition Corp.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders who received a cash payment and potential CVR. However, it marks the end of ESSA Pharma as an independent entity, which could be seen as negative for its original mission. The transaction itself is a completion of a previously announced event, so it's not a surprise.

Positives

• Shareholders received a definitive cash payment of US$0.1242 per share.
• Shareholders received contingent value rights (CVRs) offering potential additional payments of up to US$0.14 per CVR, totaling up to US$6.7 million, providing a potential upside.
• The acquisition provides a clear exit strategy and liquidity event for ESSA Pharma shareholders.

Negatives

• ESSA Pharma Inc. will cease to be an independent publicly traded company.
• Its common shares will be delisted from the Nasdaq Capital Market, removing public trading access.
• The company will terminate its registration and reporting obligations under the Exchange Act, reducing transparency.
• The CVR payment is contingent and not guaranteed, depending on the outcome and expenses of certain contingent liabilities, introducing uncertainty for the full potential value.
• ESSA's previous focus on developing prostate cancer therapies will likely be integrated or discontinued under XenoTherapeutics' xenotransplantation focus, potentially altering its original mission.

Risks

• The CVR payment of up to US$0.14 per CVR is contingent on the outcome and related expenses of certain contingent liabilities, meaning the full amount is not guaranteed.
• Potential litigation relating to the transaction could be instituted by or against the Company, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Potential exposure or liability relating to a due bill communication matter that occurred on August 25, 2025.
• Disruptions from the transaction could harm the Company's business, including current plans and operations.
• Challenges in retaining and hiring key personnel post-acquisition.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, or outbreaks of war or hostilities.
• Significant transaction costs associated with the transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitive responses to the transaction.

Future Outlook

ESSA Pharma Inc. expects its common shares to be delisted from the Nasdaq Capital Market and its registration under the U.S. Securities Exchange Act of 1934 to be terminated approximately 10 days after the closing of the acquisition, ceasing its public reporting obligations.

Management Comments

• ESSA Pharma Inc. announced the completion of XenoTherapeutics (Xeno) previously announced acquisition of ESSA (the Acquisition).

Industry Context

This acquisition represents a strategic shift for ESSA Pharma, moving from a publicly traded company focused on prostate cancer therapies to becoming a wholly-owned subsidiary under XenoTherapeutics, a non-profit focused on xenotransplantation. This could indicate a consolidation trend in the biotech sector, where smaller, specialized firms are acquired by larger entities or foundations, potentially to integrate specific assets or intellectual property into a broader research agenda. For the prostate cancer therapeutic space, this means one less independent developer, while for xenotransplantation, it signifies a potential expansion of resources or capabilities for XenoTherapeutics.

Management Changes

Corporate Governance

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.

Stakeholder Impact

• Shareholders received US$0.1242 cash per share and one CVR per share (potential for up to US$0.14 per CVR), marking a definitive exit from their investment in ESSA Pharma.
• While not explicitly stated, acquisitions often lead to restructuring and potential job impacts, though the filing does mention a risk regarding the ability to retain and hire key personnel.
• Customers and suppliers may experience changes in relationships or contracts as ESSA Pharma integrates into XenoTherapeutics.
• Previous directors resigned, and new management from the acquiring entity took control, indicating a complete change in leadership.

Next Steps

• Nasdaq to suspend trading of ESSA's shares effective before the opening of trading on October 10, 2025.
• Nasdaq to file Form 25 with the SEC to effect the delisting and deregistration of shares under Section 12(b) of the Exchange Act.
• Purchaser intends to file Form 15 with the SEC to terminate registration of shares under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
• An early warning report will be filed on SEDAR+ under ESSA's profile.

Key Dates

Recommendation

The acquisition has been completed, and ESSA Pharma Inc. shares are being delisted from the Nasdaq Capital Market. Shareholders have already received the cash consideration and CVRs. There is no longer a public market for the shares, making a 'sell' recommendation the only logical action for any remaining shareholders to realize their CVRs if they haven't already, or for those who might have missed the tender/exchange process. For new investors, there is no opportunity to 'buy' as the company is no longer publicly traded.

Keywords

ESSA Pharma, XenoTherapeutics, Acquisition, Merger, Biotechnology, Pharmaceutical, Prostate Cancer, Xenotransplantation, CVR, Delisting, SEC Filing, 8-K